<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>HEART FAILURE</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8qAt8h3m8AAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAA60lEQVRIx+2VsQqDMBRF70sCLg5OLoKgjk7+lJ/hh+STXBwcnRz8ArMEkrxOFktbaC3tULzTg5e8k5vADXDq70VbobXmvu/hvQczg4heHrJfXxQFuq67blZbMc8zpmlCXddIkgTOuZcBUko45zCOI6y1Nz2xFSEEZFmGOI7fGg4A3nsQEZqmuXOu9jallACAtm3fvmutNaIoAjM/dkBECCF89KCbk4eAb+kEnIAT8EsAM0OIz3hSyrssUvss8t5fg+uIrLXPs0gIgWVZYIyBUurQyYdheO4gz3NUVQVjDNZ1PfSjpWmKsixvehfB9GBZ3NndrgAAAABJRU5ErkJggg==)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\18.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>HEART FAILURE <a name='17:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
<img src="./Pharmacology/pasted_image.png"><img src="./Pharmacology/pasted_image001.png">
</p>

<h1>I.OVERVIEW</h1>

<p>
→ [HF] — Heart Failure<br>
<ul style='padding-left: 30pt'>
<li>complex,progressive disorder</li>
<li>heart is unable to pump sufficient blood to meet the needs of the body</li>
<li>sypmtoms : dyspnea , fatigue , fuild retention </li>
<li>impaired ability of the heart to fill with and/or pump the blood</li>
<li>abnormal increases in blood volume interstetial fluid ("congestive")</li>
</ul>
<ul>
<li>because inlude — dyspnea from pulmonary congestion in left HF and peripheral edema in right HF</li>
</ul>
→ underlying causes:<br>
<ul style='padding-left: 30pt'>
<li>arteriosclerotic heart disease</li>
<li>myocardial infranction</li>
<li>hypertensive heart disease</li>
<li>valvular heart disease</li>
<li>dilated cardiomyopathy</li>
<li>coronary artery disease</li>
</ul>
</p>

<h1>I.A.Role of physiologic compensatory mechanim in the progression of HF</h1>

<p>
→ Chronic activation of <br>
<ul style='padding-left: 180pt'>
<li>sympathetic nervous system and </li>
<li>renin-angiotensin-aldosterone system </li>
</ul>
<ul style='padding-left: 30pt'>
<li>associated with 
<ul>

<ul>

<ul>

<ul>

<ul>
<li>remodeling of cardiac tissue</li>
<li>loss of myocytes</li>
<li>hypertrophy </li>
<li>fibrosis</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</li>
<li>geometry of the hear become :
<ul>

<ul>

<ul>

<ul>

<ul>
<li>less eliptical</li>
<li>more spherical	→ [which interfering with the ability as a pump]</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</p>

<h1>I.B.Goals of pharmacologic intervention in HF</h1>

<p>
→ alleviate symptoms<br>
→ slow disease progression<br>
→ improve survival<br>
→ 6 classes of drugs have been shown to be effective<br>
<div style='padding-left: 90pt'>
 1. inhibitors of the renin-angiotensin system
</div>
<ol style='padding-left: 90pt' type="1" start="2">
<li>β-andrenoreceptor blockers</li>
<li>diuretics</li>
<li>direct vasodilators</li>
<li>inotropic agents</li>
<li>aldosterone antagonist</li>
</ol>
<ul>
<li>depending on the severity and individual patients factors.</li>
<li>one or more classes of the drug are admin.</li>
</ul>
→ benificial effectos of the pharmacological intervention <br>
<ul style='padding-left: 30pt'>
<li>reduction of the load on the mycoardium</li>
<li>decreased extracellular fluid volume</li>
<li>improved cardiac contractility </li>
<li>slowing the rate of the cardiac remodeling</li>
</ul>
</p>

<h1>II.PHYSIOLOGY OF THE MUSCLE CONTRACTION</h1>

<p>
→ Myocardium , like smooth/skeletal muscle respond to stimulation by depolarization of the membrane<br>
<ul style='padding-left: 30pt'>
<li>followed by shortening of the cotractile proteins → relaxation and return to the resting state</li>
</ul>
→ but act as interconnected in groups that respond to stimuli as a unti.<br>
<ul style='padding-left: 30pt'>
<li>whenever a single cell stimualted</li>
</ul>
</p>

<h1>II.A.Action Potential</h1>

<p>
→ are electrically excitable<br>
→ intrinsic rythm generated by specialed cells <br>
<ul style='padding-left: 30pt'>
<li>called "pacemakers"</li>
<li>located in the sinoartial and antriventricular(AV) nodes.</li>
<li>ions pass through channels [to induce depolarization/repolarization] in the sarcolemmal membrane → "<i>create a current"</i></li>
</ul>
→ Some respond primarly in changes to ion concentration<br>
<ul style='padding-left: 30pt'>
<li>whereas others are sensitive to adonesine triphosphate or to membrane voltage.</li>
</ul>
</p>

<h1>II.B.Cardiac Contranction</h1>

<p>
→ direclty related to the concentration of free (UNBOUND) cytostolic calcium.<br>
→ agents that increase these calcium levels<br>
<ul style='padding-left: 30pt'>
<li>increase the force of the contraction (inotropic effect)</li>
</ul>
→ increase in the cotractility of the heart <br>
<ul style='padding-left: 30pt'>
<li>directly/indirectly alerting the mechanism of control of intracellular calcium</li>
</ul>
</p>

<h1>II.B.1 Sources of free intracellular calcium</h1>

<p>
→ outside the cell<br>
→ also enter by exchange with sodium<br>
→ also released from sarcoplasmataic recticulum and mitochondria		<br>
<ul style='padding-left: 30pt'>
<li>which further increases the cytostolic lever of calcium.</li>
</ul>
</p>

<h1>II.B.2 Removal of free cytostolic calcium.</h1>

<p>
→ free cytostolic calcium were to to remain high	<br>
<ul style='padding-left: 30pt'>
<li>we would have a constant contracntion of the heart muscle</li>
</ul>
</p>

<h1>II.B2.a.Sodium/Calcium exchange:</h1>

<p>
→ sodium/calcium echange reaction that revesible exchanges calcium ions for sodium ions.<br>
<ul style='padding-left: 30pt'>
<li>which can affect cellular levels of calcium</li>
</ul>
</p>

<h1>II.B2.b.Upatke of calcium by the sarcoplasmatic recticulum and mitochondria.</h1>

<p>
→ recaptured by the sarcoplasmatmic recticulum and mitochondria.<br>
→ more than 99% of the intracellular calcium is located in these organlles.<br>
<ul style='padding-left: 30pt'>
<li>and even a modest shift between em can lead to :</li>
<li>a large change in the concentration of free cytostolic calcium</li>
</ul>
</p>

<h1>II.C.Compensatory physiological responses in HF</h1>

<p>
→ compnsatory mechanims enhance cardiac output<br>
<ul style='padding-left: 30pt'>
<li>although initially benificial → further deterioration of cardiac funciton </li>
</ul>
</p>

<h1>II.C.1. Increased sympathetic activity</h1>

<p>
→ decrease in blood pressure — &gt;activate sympathetic nervous system<br>
<ul style='padding-left: 30pt'>
<li>sustain tissue perfusion → stilmulation of β-andrenergic receptors 	
<ul>
<li>→ increased heart rate → greater force of contraction of the heart muscsle</li>
</ul></li>
</ul>
→ vasoconstriction (a1-mediated) enchances venous return and increases cardiac preload<br>
→ the work of the heart , in the long term , contribute to further delcine in cardiac function.
</p>

<h1>II.C.2. Activation of the renin-angiotensin system</h1>

<p>
→ decrease in blood flow to the kidney  → prompting of release of renin<br>
<ul style='padding-left: 30pt'>
<li>→ increase formataion of angiotensin II and release <i>aldosterone.</i></li>
<li>increased peripheral resistance and retention of sodium and water</li>
</ul>
→ blood volume increases,and more blood returned to the heart<br>
<ul style='padding-left: 30pt'>
<li>if heart is unable to pump this extra volume → venous pressure increases
<ul>
<li>peripheral edema + pulmonary edema occurs</li>
</ul></li>
</ul>
→ increase in the work of the heart → further decline in cardiac function 
</p>

<h1>II.C.3.Myocardial hypertrophy</h1>

<p>
→ heart in size increased<br>
<ul style='padding-left: 30pt'>
<li>chamber dilate</li>
<li>more globular</li>
</ul>
→ streching of the heart muscle leads to stronger contranction <br>
excessive enolgation of the fibers results in weaker contranction.<br>
→ geometry dismish the ablility to eject blood<br>
→ "systolic failure" → ventricle unable to pump effectively<br>
→ "diastolic dysfunction" → impaired by structual change such as hypertrophy<br>
<ul style='padding-left: 30pt'>
<li>thickening of the ventricular wall 
<ul>
<li>subsequent decrease in ventricular volume decrease</li>
</ul></li>
</ul>
<ul>
<li>ability of heart muscle to relax</li>
</ul>
→ ventricle does not fill adequately <br>
<ul style='padding-left: 30pt'>
<li>indaquacy of cardiac output is term "diastolic HF --&gt;[ common feature on elderly woman]</li>
</ul>
→ Distolic dysfunction 	<br>
<ul style='padding-left: 30pt'>
<li>pure form characterized by signs and symptoms of HF</li>
<li>presence of normal function of the left ventricle</li>
</ul>
→ both systolic and diastolic dysfunctions commonly coexist in HF
</p>

<h1>II.C.3.Decompensated HF</h1>

<p>
→ adaptive mechanism adequately <br>
<ul style='padding-left: 30pt'>
<li>restore cardiac output 
<ul>
<li>HF said to be "compensated"</li>
</ul></li>
</ul>
→ compensations increase the work of the heart and contribute to further decline in cardiac performane<br>
→ if adaptive mechanims faial to maintain cardiac output <br>
<ul style='padding-left: 30pt'>
<li>HF is decompensated</li>
</ul>
</p>

<h1>II.C.4.Therapeutic strategies in HF</h1>

<p>
→ reduction in physical activity<br>
→ low dietary intake of sodium (&lt;1500mg/day)<br>
→ treatment of cmorbid condition<br>
→ judicious use of diuretics<br>
→ inhibitors of the renin-angiotensin system<br>
→ DRUGS may perticipate / exacerbate HF such as:<br>
<ul style='padding-left: 30pt'>
<li>NSADs</li>
<li>alcochol </li>
<li>caclium-channel blcokers</li>
<li>high dose β-blcokers</li>
<li>antiarrythmics                          → should be avoided if possible</li>
</ul>
→ Patients with HF compain about <br>
<ul style='padding-left: 30pt'>
<li>dyspnea</li>
<li>exertion </li>
<li>orthopnea</li>
<li>paroxysmal nacturnal dyspnea</li>
<li>fatigue </li>
<li>dependnt edema</li>
</ul>
</p>

<h1>III.INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM</h1>

<p>
→ HF leads to activation of the renin-angiotensin system via two mechanism <br>
<ol style='padding-left: 30pt' type="1" start="1">
<li>↑ renin release into the afferent arterioles 
<ul>
<li>in response to the dishmished renal perfusion pressure produced by the failing heart.</li>
</ul></li>
</ol>
<div style='padding-left: 30pt'>
2.renin  release is promoted by sympathetic stimulation and activation of β-receptors
</div>
→ production of angiotensin II → potent vasoconstriciton and subsequent stimulation of aldosterone release<br>
<ul style='padding-left: 30pt'>
<li>that causes salts and water retention  → ↑ preload/afterload that are characteristic that the heart is failing </li>
<li>favoring remodeling / fibrosis / inflammatory changes</li>
</ul>
</p>

<h1>III.A - Angiotensin - converting enzyme inhibitors [ACE]</h1>

<p>
→ ACE<br>
<ul style='padding-left: 30pt'>
<li>agents of choice in HF</li>
</ul>
→ block the enzyme that cleaves angiotensin I to form the potent vasoconstrictor angiotensin II<br>
<ul style='padding-left: 30pt'>
<li>dismish the rate of bradykinin inactivation</li>
</ul>
[Vasodilation occurs as a result of the combined effect of lower vasoconstriction caused by diminished levels of angiotensin II  and increased bradykinin (potent vasodilating effect)].<br>
→ by ↓ circulating angiotensin II levels<br>
<ul style='padding-left: 30pt'>
<li>ACE inhibitors also ↓ the secretion of aldosterone → ↓ sodium and water retentino </li>
</ul>
</p>

<h1>III.A.1-Actions on the heart</h1>

<p>
→ ↓ vascular resistence / ↓ venous tone / ↓ blood pressure<br>
→ these drugs reduce <br>
<ul style='padding-left: 30pt'>
<li>preload/afterload → ↑ cardiac output </li>
</ul>
→ blunt the usual angiotensin II-mediated ↑ in epinephrine and aldosterone seen in HF<br>
→ improve clinical symptoms in patients also recieving<br>
<ul style='padding-left: 30pt'>
<li>thiazide / loop diuretics / digoxin</li>
</ul>
→ use of ACE → ↓ morbidity + mortality <br>
→ treatment with <i>enalapril</i><br>
<ul style='padding-left: 30pt'>
<li>↓ arrhythmic death , myocardial infranction , strokes.</li>
<li><img src="./Pharmacology/pasted_image002.png"></li>
</ul>
</p>

<h1>III.A.2-Indication</h1>

<p>
→ may be considered for <br>
<ul style='padding-left: 30pt'>
<li>single-agent therapy </li>
</ul>
→  in patients with <br>
<ul style='padding-left: 30pt'>
<li>with all stages of left ventricular failure</li>
<li>with lowest rejection fraction show the greatest benifit from use of ACE inhibitors</li>
<li>with recent myocardial infranction  also benifit form long-term therapy wiht ACE-inhibitors.</li>
</ul>
→ also may be used in combination with <br>
<ul style='padding-left: 30pt'>
<li>diuretics </li>
<li>β-blcokers</li>
<li>digoxin</li>
<li>aldosterone antagonist</li>
</ul>
</p>

<h1>III.A.3.-Pharmacokinetics</h1>

<p>
→ all ACE inhibitors adequately but incompletely absorbed following oral admin.<br>
→ presence of foold ↓ absorption  [ should be taken with empty stomach]<br>
→ except of <i>Catopril</i><br>
<ul style='padding-left: 30pt'>
<li>pro-drug that require activation by hydrolysis via hepatic enzymes</li>
</ul>
→ renal elimination of the active moiety is importnant for most ACE inhibitors<br>
<ul style='padding-left: 30pt'>
<li>with exception of <i>Fosinopril </i></li>
<li>plasma half-life : 2 to 12 hours</li>
</ul>
→ Newers compounds such as <br>
<ul style='padding-left: 30pt'>
<li><i>Ramipril and Fosinopril </i>requires only once-a-day dosing.</li>
</ul>
</p>

<h1>III.A.3-Adverse effects</h1>

<p>
→ postural hypotention , renal insufficient hyperkalemia , angioedema , dry cough<br>
→ potential for symptomatic hypotention with ACe-inhibitors therapy requires careful monitoring<br>
→ agents are toxic to the fetus
</p>

<h1>III.B.-ANGIOTENSIN-RECEPTORS BLOCKERS [ABRs]</h1>

<p>
→Angiotensin - receptor blockers ARBs<br>
<ul style='padding-left: 30pt'>
<li>nonpeptide compounds</li>
<li>orally active</li>
<li>extremely potent competive antagonist of the angiotensin type 1 receptor</li>
</ul>
→ <i>Losartan</i><br>
<ul style='padding-left: 30pt'>
<li>prototype durg</li>
</ul>
→ ABRs have the advantage of more complete of more complete blockage of angiotensin aciton<br>
<ul style='padding-left: 30pt'>
<li>cuz ACEinhibitors inhibit only the enzyme responsible for the 
<ul>
<li>production of angiotensin II</li>
</ul></li>
</ul>
→ do not affect bradykinin levels<br>
→ even though similar actions to those of ACE , they are not therapeutically identical 
</p>

<h1>III.B.1-Action on the cardiovascular system</h1>

<p>
→ ABRS are approved for the treatment of hypertention <br>
<ul style='padding-left: 30pt'>
<li>by lowering blood pressure </li>
<li>reducing morbidity and mortality  associated with hypertension</li>
</ul>
→ in use for HF<br>
<ul style='padding-left: 30pt'>
<li>as substitute of ACE's inhibitors in those patients with</li>
</ul>
<ul>
<li>severe cough <a href="file:///C:/" title="/" class="file">/</a> angioedema</li>
</ul>
</p>

<h1>III.B.2-Pharmacokinetics</h1>

<p>
→ all the drugs are orally active<br>
→ require "once a day dosing"<br>
→ <i>Losartan </i><br>
<ul style='padding-left: 30pt'>
<li>first member of the class</li>
<li>differs from the others that undergo extensive first-pass hepatic metabolism </li>
<li>including convertion ot its active metabolite</li>
</ul>
→ they other drugs have inactive metabolite<br>
→ elimination of metabolites/parent compounds happned in urine/feces<br>
→ propotion is dependent on the individual drug<br>
→ all are highly plasma protein  bound (greater than 90%)<br>
→ except <i>Candesartan</i><br>
<ul style='padding-left: 30pt'>
<li>have large volumes of distribution.</li>
</ul>
</p>

<h1>III.B.3-Adverse Effects</h1>

<p>
→ adr profile similar to those of ACE<br>
→ ABR's does not produce cough <br>
→ also CI in pregnancy
</p>

<h1>IV. β-BLOCKERS</h1>

<p>
→ all clinicaly β-blockers are competative inhibitors<br>
→ non-selective β-bockers act on both β1+β2 receptors<br>
→ <br>
→ negative inotropic activity <br>
→ but <br>
<ul style='padding-left: 30pt'>
<li>improve systolic functioning </li>
<li>reverse cardiac remodeling</li>
</ul>
→ they shows their benifit on <br>
<ul style='padding-left: 30pt'>
<li>ability to prevent the changes that occur of the chronic activation of sympathetic system</li>
<li>↓ heart rate</li>
<li>inhibiting the release of renin </li>
</ul>
→ in addition,β-blcoker<br>
<ul style='padding-left: 30pt'>
<li>prevent the direct deleterious effects of norepinephrine on the cardiac muscsle fibers</li>
<li>↓ remodeling , hypertrophy  and cell death.</li>
</ul>
→ treating<br>
<ul style='padding-left: 30pt'>
<li>angina </li>
<li>cardiac arrythmias</li>
<li>myocardial infranction</li>
<li>congstive heart failure</li>
<li>hyperthyroism</li>
<li>glaucoma</li>
<li>prophylaxis of migrain headaches.</li>
</ul>
</p>

<p>
→ Two β-blockers have been approved:<br>
<ul style='padding-left: 30pt'>
<li><i>Carvedilol </i></li>
</ul>
<ul>
<li>non-selective β-adrenoreceptor antagonist that also blocks α-adrenoreceptors.</li>
</ul>
</p>

<p>
<ul style='padding-left: 30pt'>
<li>long-acting <i>Metoprolol </i></li>
</ul>
<ul>
<li>β1-selective antagonist</li>
</ul>
→ B-blockage is recommended to all patients with heart disease<br>
<ul style='padding-left: 30pt'>
<li>reduce morbidity &amp; mortality associated with HF</li>
</ul>
→ dosage : <br>
<ul style='padding-left: 30pt'>
<li>should start slow and titrate gradually based on patients tolerance.</li>
</ul>
→ Hypertensives will also benifit of the admin. of β-blockers.
</p>

<h1>IV.1.-CARVEDILOL</h1>

<p>
→β-blockers with concurrent α1-blocking actions that produce [is a non-selective β-adrenoreceptor antagonist] <br>
<ul style='padding-left: 30pt'>
<li>peripheral vasodilatoin </li>
<li>↓ blood pressure</li>
</ul>
[they contrast with the other β-blockers that produce peripheral vasoconstriction]<br>
→ ↓ lipid peroxidation &amp; vascular wall thickening → [effects that benifit in heart failure]<br>
<img src="./Pharmacology/pasted_image003.png"><br>
<img src="./Pharmacology/pasted_image004.png"><br>
→ Acute admin. of β-blcokers can trigger:<br>
<ul style='padding-left: 30pt'>
<li>congestive heart failure </li>
<li>worsen the condition</li>
</ul>
→ however clinical benifits have shown with <br>
<ul style='padding-left: 30pt'>
<li><i>carvedilol metoprolol bisoprolol	</i></li>
<li>↓ mortality </li>
<li>prevent cardiovascular mortalities.</li>
</ul>
</p>
<h1>IV.2-ATENOLOL</h1>

<p>
→ mots commonly prescribed β-blockers<br>
→ β1-selective group<br>
→ may be safer in patient who experience "bronchoconstrinction" in response to propanolol.
</p>

<br>

<h1>V.-DIURETICS</h1>

<p>
→ relieve pulmonary congestion &amp; peripheral edema.<br>
→ useful in reducing the symptoms of volume "overload"<br>
<ul style='padding-left: 30pt'>
<li>including — orthopnea — paroxysmal nocturnal dyspnea</li>
</ul>
→ ↓ venous return to the heart (preload)<br>
<ul style='padding-left: 30pt'>
<li>also ↓ "afterload" — [by ↓ plasma volume  → ↓ blood pressure]</li>
</ul>
→ Thiazide diuretics<br>
<ul style='padding-left: 30pt'>
<li>mild diuretics</li>
<li>creatine clearence is less than 50 mL/min.</li>
</ul>
→ Loop diuretics<br>
<ul style='padding-left: 30pt'>
<li>extensive diuresis  and those with renal insufficiency </li>
<li>are the most commonly used in diuretics in HF</li>
<li>overdose → profound hypovolemia.</li>
</ul>
</p>

<h1>VI.-DIRECT VASODILATORS</h1>

<p>
→dilation of venous blood vessels → ↓ in cardiac "preload" by ↑ the venous capacitance.<br>
→ reduce systemeic arteriolar resistance &amp; ↓ afterload<br>
→ Nitrates <br>
<ul style='padding-left: 30pt'>
<li>↓ preload</li>
<li>venous dilators for patients with congestive HF.</li>
<li>if intolerance of ACE inhibitors or β-blcokers</li>
</ul>
<ul>
<li>or if additional vasodilators response is required, a combination of <i>hydralazine </i>and <i>isosorbide dinitrate</i></li>
</ul>
<div style='padding-left: 480pt'>
 — ↓ afterload 
</div>
</p>

<h1>VII-INOTROPIC DRUGS</h1>

<p>
→ (+)-positive inotropic agents<br>
<ul style='padding-left: 30pt'>
<li>enhance cardiac muscle contractility  → ↑ cardiac output </li>
</ul>
→ these drugs act by different mechanism<br>
<ul style='padding-left: 30pt'>
<li>↑ cytoplasmatic Ca+2 concentration that enchance the contractility of cardiac muscle.</li>
</ul>
</p>

<h1>VII.A.-DIGITALIS GLYCOSIDES</h1>

<p>
→ cardiac glycosides<br>
<ul style='padding-left: 30pt'>
<li>often called "digitalis" <a href="file:///C:/" title="/" class="file">/</a> "digitalis glycosides"</li>
</ul>
→ Drugs come from 	<br>
<ul style='padding-left: 30pt'>
<li>digitalis (foxglove) plant.</li>
</ul>
→ widely used in treatment of HF<br>
→ infulence the <br>
<ul style='padding-left: 30pt'>
<li>sodium and calcium ion flows in the cardiac muscle</li>
<li>↑ contraction of the artial and ventricular myocardium — [positive inotropic action]</li>
</ul>
→ the compound called "<i>digoxin".</i>
</p>

<h1>VII.A.1-Mechanism of actions</h1>

<br>

<h1>VII.A.1.a-Regulation of cytostolic calcium concentration</h1>

<p>
→ free cytostolic calcium conc. at the end of the contraction must be ↓  for cardiac muscle to relax<br>
→ Na+/Ca+2 exchanger<br>
<ul style='padding-left: 30pt'>
<li>extruding Ca+2 from the myocyte</li>
<li>in exchange for Na+.</li>
</ul>
→ conc. gradient for both ions is the major determinant for the movement of ions.	<br>
→ by inhibiting the actively pump Na+ from the cell<br>
<ul style='padding-left: 30pt'>
<li>cardiac glycosides ↓ Na+ conc.gradient → ↓ ability of the Na+/Ca+2 exchanger to move Ca+2 OUT of the cell. </li>
</ul>
→ higher cellular Na+ → ↑ intracellular Ca+2 → ↑ muscsle contractility <br>
<ul style='padding-left: 30pt'>
<li>because of Na+/ATPase exchanges 2Na for 1K+</li>
<li>restores the ion conc. and the membrane resting potential.</li>
</ul>
→ when the Na+/K+-adenosine triphosphatase is inhibited by <i>digoxin</i><br>
<ul style='padding-left: 30pt'>
<li>resting membrane potential may ↑ </li>
<li>which make the membrane more excitable ↑ arrythmias [which considered to be toxicity]</li>
<li><img src="./Pharmacology/pasted_image005.png"></li>
</ul>
</p>

<h1>VII.A.1.b-Increased contractility of the cardiac muscle</h1>

<p>
→ ↑ the force of cardiac contraction<br>
<ul style='padding-left: 30pt'>
<li>causing the cardiac output to the "normal heart"</li>
</ul>
→ ↑ myocardial contranction → ↓ in end-diastolic volume → ↑ efficiency of contranction. (↑ ejeciton fraction )<br>
→ improved circulation → ↓ sympathetic activity <br>
<ul style='padding-left: 120pt'>
<li>together THESE effects cause a — reduction in <i>heart rate — </i></li>
</ul>
→ Vagal tone is ↑ <br>
<ul style='padding-left: 30pt'>
<li>so heart rate ↓ &amp; myocardial oxygen demand diminishes </li>
</ul>
→ <i>Digoxin </i><br>
<ul style='padding-left: 30pt'>
<li>slow conduction velocity through AV nodes [ which used in artial fibrilation]</li>
</ul>
</p>

<h1>VII.A.2.-Therapeutic Use</h1>

<p>
→ severe left ventricular systolic dysfunction  after initiation of ACE inhibitor and diuretic therapy<br>
→ not indicated i patients which diastolic / right-sided HF<br>
→ major use in HF with artial fibrilation
</p>

<h1>VII.A.3.-Pharmacokinetics</h1>

<p>
→ very potent<br>
→ long half-life : 36 hours<br>
→ may eliminated intact by the kidneys<br>
<ul style='padding-left: 30pt'>
<li>require adjustement in dose based on creatine clearence.</li>
</ul>
→ large volume distribution<br>
<ul style='padding-left: 30pt'>
<li>because its accumulates in muscle</li>
</ul>
→ dosage based on lean body weight<br>
<img src="./Pharmacology/pasted_image006.png">
</p>

<h1>VII.A.4.-Adverse effects</h1>

<p>
→ digoxin toxicity <br>
→ discontiniuing cardiac glycosides<br>
→ determing serum potassium levels<br>
<ul style='padding-left: 30pt'>
<li>[↓ K+ increases the potential for cardiotoxicity]</li>
</ul>
→ monitor also in renal insufficient cases<br>
→ cardiac effects<br>
<ul style='padding-left: 30pt'>
<li>arrythmia,</li>
</ul>
→ gastrointenstinal effects<br>
<ul style='padding-left: 30pt'>
<li>anorexia, nausea,vomiting are commonly ecountered </li>
</ul>
→ central nervous systeem<br>
<ul style='padding-left: 30pt'>
<li>headache , fatigue , confusion , blurred vision , alteration of colour perception , halos of dark objects</li>
</ul>
<img src="./Pharmacology/pasted_image007.png">
</p>

<h1>VIII. ALDOSTERONE ANTAGONIST</h1>

<p>
→ advanced heart disease have elevated of aldosterone due to :	<br>
<ul style='padding-left: 30pt'>
<li>angiotensin II stimulation </li>
<li>↓ hepatic clearence of the hormone.</li>
</ul>
→ <i>Spirolactone </i><br>
<ul style='padding-left: 30pt'>
<li>direct antagonist of aldosterone</li>
<li>preventing salt retention </li>
<li>myocardial hypertrophy</li>
<li>hypokalemia</li>
<li>promotes potassium retention</li>
</ul>
→ Adverse effects:<br>
<ul style='padding-left: 30pt'>
<li>gastric disturbances  — gastritis &amp; peptic ulcer</li>
<li>central nervous system effects — lethargy — confusion</li>
<li>endocrine abnormalities  — gynecomastia , ↓ libido , </li>
</ul>
→ <i>Eplerenone </i><br>
<ul style='padding-left: 30pt'>
<li>competative antagonist  of aldosterone at mineralocorticoid receptor</li>
<li>reduce affinity for glucocorticoid , androgen , progesterone receptors  [in contrast with spirolactone]</li>
<li>reduce mortality in patients with left ventricular systolic dysfunction and HF after acute myocardial infraction.</li>
</ul>
</p>

<h1>IX.-ORDER OF THERAPY</h1>

<p>
→ classified HF into 4 stages<br>
<ul style='padding-left: 30pt'>
<li>from least severe to most severe</li>
</ul>
<img src="./Pharmacology/pasted_image009.png"><br>
→ as the disease progress — polytherapy is initiated<br>
→ Overt heart failure<br>
<ul style='padding-left: 30pt'>
<li>loop diuretics are iften nitrduced first to reliefe of signs or symptoms of volume overload [dyspnea,peripheral edema]</li>
</ul>
→ ACE inhibitors or ARB's are added after the optimization with diuretics<br>
<ul style='padding-left: 30pt'>
<li>gradually titrate dosage </li>
</ul>
→ β-Blockers<br>
<ul style='padding-left: 30pt'>
<li>initiated after the patients is stable on ACE inhibitiors</li>
<li>gradually titrate dosage</li>
</ul>
→ Digoxin<br>
<ul style='padding-left: 30pt'>
<li>continue to have symptoms of HF despite the multiple drug therapy.</li>
</ul>
</p>

<br>
<br>

<p>
<img src="./Pharmacology/pasted_image010.png"><br>
<img src="./Pharmacology/pasted_image011.png"><br>
<img src="./Pharmacology/pasted_image012.png"><br>
<img src="./Pharmacology/pasted_image013.png">
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>55.9kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>40.6kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>109kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>55.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>56.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>99.4kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>25.4kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>43.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image008.png'>pasted_image008.png</a></td><td>&nbsp;</td><td>100kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image009.png'>pasted_image009.png</a></td><td>&nbsp;</td><td>100kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image010.png'>pasted_image010.png</a></td><td>&nbsp;</td><td>134kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image011.png'>pasted_image011.png</a></td><td>&nbsp;</td><td>274kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image012.png'>pasted_image012.png</a></td><td>&nbsp;</td><td>53.4kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image013.png'>pasted_image013.png</a></td><td>&nbsp;</td><td>232kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
